The Global Health Body Sounds Alert Over Critical Lack of Obesity Medications
Less than one in 10 individuals eligible to benefit from weight-loss injections such as Wegovy have access to them, states the WHO as it issues its first advice on the medications.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging more widespread and fairer availability to this class of drugs.
Per estimates, more than two billion will be obese by 2030 without intervention.
"Our new guidelines recognises that excess weight is a lifelong illness that can be addressed with holistic and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are key barriers to widespread access to the treatments that can help people shift substantial body mass, explains the body.
Weight-Loss Drug Scarcity
Even under the current best projected scenario, the supply of GLP-1 therapies would only suffice for about 100 million people – fewer than 10% of eligible patients, according to the WHO.
The recommendation calls on nations and manufacturers to expand access, by measures like patent sharing.
Exclusive production rights on semaglutide – the primary component of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Injections Function
These medications imitate a body's own hormone to delay gastric emptying, curb appetite and increase satiety so people eat less.
People commonly see weight reduction after several weeks of commencing the once-weekly jabs.
Research points to users may see weight return after a year of stopping the treatment, because their typical hunger come back.
To be overweight or obese raises your likelihood for experiencing diseases, like diabetes, heart disease, stroke, and some malignancies.
Obesity impacts people in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, as per the health agency.
